SentryBond-based Opioid Products
Pain Management (with abuse-deterrent properties)
Pre-clinicalActive
Key Facts
Indication
Pain Management (with abuse-deterrent properties)
Phase
Pre-clinical
Status
Active
Company
About Protega Pharmaceuticals
Protega Pharmaceuticals is a private, pre-revenue biotech founded in 2014, targeting the opioid abuse crisis with its proprietary SentryBond abuse-deterrent formulation technology. Led by industry veterans, the company is developing a line of immediate-release abuse-deterrent opioid products, positioning itself in the high-need but competitive generic and specialty pain management sector. Its success hinges on navigating complex regulatory pathways, achieving product differentiation, and securing commercialization partnerships to bring its therapies to market.
View full company profile